All Oncology News

Pirtobrutinib, showcased promising efficacy signals across dose levels in previously treated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

The effectiveness of this treatment in patients with multiple myeloma may be an option for a patient population who represent an unmet need.

Various phase 2 and 3 studies are currently underway utilizing both new and existing treatments in an effort to improve outcomes for patients with myelofibrosis.

Flexibilities in time and place were effective strategies to mitigate COVID–19-related patient concerns and to increase participation in international lung cancer clinical trials.

The safety and efficacy of the quadruplet regimen of fixed-dose isatuximab-irfcc in combination with bortezomib, lenalidomide, and dexamethasone were confirmed for patients with newly diagnosed multiple myeloma with no immediate intent for transplant.

Future treatment approaches for patients with polycythemia vera (PV) should center around adapting therapy using the available criteria, and eventually finding new targets.

For patients with myeloma have undergone an autologous stem cell transplant and are currently on maintenance therapy with lenalidomide, minimal residual disease may be a powerful predictor of outcomes.

Older patients with newly diagnosed multiple myeloma who are ineligible for chemotherapy or transplant may derive a greater benefit when treated with daratumumab plus lenalidomide and dexamethasone compared with lenalidomide and dexamethasone.

The addition of venetoclax to fludarabine, cytarabine, idarubicin and G-CSF resulted in high complete response rates and enables a high consolidative allogeneic transplantation rate in patients with newly diagnosed acute myeloid leukemia.

David J. Feller-Kopman, MD, discusses the imperative role of the pulmonologist in the screening and management of lung cancer.

Iberdomide combined with dexamethasone and either daratumumab, bortezomib, or carfilzomib showed efficacy and tolerability in patients with relapsed or refractory multiple myeloma.

Updated data from a phase 2 trial presented at the 2021 World Conference on Lung Cancer showed that neoadjuvant osimertinib induced a pathologic complete response among patients with surgically resectable EGFR-mutant non–small cell lung cancer.

Mobocertinib demonstrated clinical activity in previously platinum-treated patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer whether or not they received a prior PD-1/PD-L1 inhibitor.

The United Kingdom’s National Institute of Health and Care Excellence has recommended apalutamide for use in combination with androgen deprivation therapy in patients with high-risk hormone-relapsed nonmetastatic prostate cancer and in those with hormone-sensitive metastatic prostate cancer if docetaxel is not suitable or cannot be tolerated.

Because standardized treatment approaches have not been established for patients with low-risk myelodysplastic syndromes and limited options are available to those with erythropoietin failure, the need for varied clinical trials is underscored.

The combination of ado-trastuzumab emtansine and osimertinib demonstrated minimal antitumor effects on patients with EGFR-mutated non–small cell lung cancer, according to interim data of the phase 2 TRAEMOS trial.

Selpercatinib demonstrated robust and durable efficacy with a favorable safety profile in Chinese patients with advanced, RET fusion–positive non–small cell lung cancer.

Sotorasib elicited systemic durable anticancer activity with intracranial complete responses and continued intracranial stabilization in patients with KRAS G12C–mutated non–small cell lung cancer and stable brain metastases previously treated with radiation or surgery.

Approximately 20% of patients with malignant pleural mesothelioma were diagnosed with COVID-19 during the first year of the pandemic at the Vall d’Hebron University Hospital, leading to a high hospitalization and mortality rate.

Tislelizumab plus chemotherapy demonstrated clinically meaningful improvements in progression-free survival vs standard of care chemotherapy as a first-line treatment for patients with stage IIIB and those with stage IV advanced squamous non–small cell lung cancer.

The combination of osimertinib plus pelcitoclax demonstrated an acceptable safety profile and preliminary efficacy at the recommended phase 2 dose in patients with EGFR-positive non–small cell lung cancer that is resistant to third-generation EGFR inhibitors or treatment naïve.

In recent years, significant advances have been made regarding the treatment of patients with chronic graft-vs-host disease, with investigators developing an understanding of the pathophysiology of the disease, as well as how to integrate novel treatment modalities.

In patients with advanced RET fusion–positive non-small cell lung cancer, pralsetinib demonstrated promising results regardless of previous therapies.

The National Medical Products Administration in China has approved pembrolizumab for use in combination with platinum- and fluoropyrimidine-based chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic esophageal carcinoma or gastroesophageal junction cancer.

Adjuvant treatment with pembrolizumab led to a significant improvement in disease-free survival compared with placebo after nephrectomy in patients with renal cell carcinoma who are at high risk for recurrence, as underscored by data from the pivotal phase 3 KEYNOTE-564 trial.

ADP-A2AFPspecific peptide enhanced affinity receptor T cells were associated with an acceptable safety profile and elicited antitumor activity in patients with advanced hepatocellular carcinoma.

The combination of pembrolizumab and lenvatinib led to a statistically significant improvement in progression-free survival and overall survival in patients with mismatch repair deficient advanced endometrial cancer following platinum-based chemotherapy.

David J. Pinato, MD, discusses combination strategies in HCC, how to manage associated toxicities, and how safety profiles can help to inform treatment decisions for this patient population.

The risk of cancer-specific death was significantly higher than the risk of noncancer death in patients with neuroendocrine tumors, despite the reported heterogeneity by primary tumor site.

Nivolumab elicited a prolonged clinical benefit in patients with advanced hepatocellular carcinoma regardless of prior sorafenib.